5-amino-1MQ is a small molecule drug whose primary function is to block the activity of an enzyme called Nicotinamide N-Methyltransferase (NNMT). Nicotinamide N-methyltransferase (NNMT) has been implicated in several diseases such as osteoarthritis, insulin resistance, metabolic disorders, cardiovascular disease, cancer, obesity, kidney disease, and Parkinson’s disease.
Higher NNMT expression and MNA concentrations trigger the downstream signaling leading to insulin resistance and supplementing with 5-Amino-1-Methylquinoline blocks this from taking place resulting in weight loss at preserved food intake on a high-fat diet.
One of the primary age-related weight loss snags occurs because of an enzyme called NNMT (nicotinamide N-methyltransferase). This enzyme that in humans is encoded by the NNMT gene found on Chromosome 11. NNMT is harmful for health in several ways. Undesirably high concentrations of NNMT in the blood also drive these other diseases in addition to obesity: Osteoarthritis, Cardiovascular disease, Parkinson’s disease, Kidney disease, Metabolic disorders.
By blocking NNMT, 5-amino-1MQ stimulates an increase in NAD+, a cofactor that is central to cellular metabolism, thereby increasing metabolic rate and activating a gene called sirtuin-1 (SIRT1). SIRT1 is also known as the "longevity gene".
In addition to aiding weight loss, 5-amino-1MQ may exert the following beneficial effects in those who take it through supplementation:
NMN (NICOTINAMIDE MONONUCLEOTIDE)
Orally administered NMN was quickly utilized to synthesize NAD+ in tissues. Remarkably, NMN effectively mitigates age-associated physiological decline. Without any obvious toxicity or deleterious effects, NMN suppressed age-associated body weight gain, enhanced energy metabolism, promoted physical activity, improved insulin sensitivity and plasma lipid profile, and ameliorated eye function and other pathophysiologies.
Consistent with these phenotypes, NMN prevented age-associated gene expression changes in key metabolic organs and enhanced mitochondrial oxidative metabolism and mitonuclear protein imbalance in skeletal muscle. These effects of NMN highlight the preventive and therapeutic potential of NAD+ intermediates as effective anti-aging interventions in humans.
JBSNF-000088 is an inhibitor of nicotinamide N-methyltransferase; reduces visceral white adipose tissue (WAT) MNA levels, body weight, fed blood glucose levels, plasma and liver triglyceride levels and improves oral glucose tolerance.